Tubulis Technologies
Last updated: November 15, 2025
Founders: Dominik Schumacher, Jonas Helma
Country: Germany | Funding: €508M (+)
Founded: 2012
Website: http://tubulis.com/
Tubulis produces uniquely matched antibody-drug conjugates with exceptional biophysical properties that have shown durable on-tumor delivery and long-lasting anti-tumor activity. Its P5 Conjugation Technology allows to quickly generate highly stable ADCs with chemical flexibility that provides the potential to develop truly differentiated ADCs. Leveraging this technology, the Tubutecan Platform allows stable, high DAR 8 conjugation of potent topoisomerase-I inhibitors with improved on-target delivery and decreased off-target toxicity – without compromising ADC properties. The company is developing a portfolio of ADCs that can target previously unreachable targeting molecules and carry novel payloads.
Founded: 2012
Website: http://tubulis.com/
Tubulis produces uniquely matched antibody-drug conjugates with exceptional biophysical properties that have shown durable on-tumor delivery and long-lasting anti-tumor activity. Its P5 Conjugation Technology allows to quickly generate highly stable ADCs with chemical flexibility that provides the potential to develop truly differentiated ADCs. Leveraging this technology, the Tubutecan Platform allows stable, high DAR 8 conjugation of potent topoisomerase-I inhibitors with improved on-target delivery and decreased off-target toxicity – without compromising ADC properties. The company is developing a portfolio of ADCs that can target previously unreachable targeting molecules and carry novel payloads.
